Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7913606 | 0.86 | PIM1 (0.44) | HTR2APIM1ATMCYP2D6KDM4E | |
| SCHEMBL28963564 | 0.86 | HTR2A (0.38) | HTR2APIM1ATMCYP2D6KDM4E | |
| SCHEMBL30071558 | 0.86 | HTR2A (0.38) | HTR2APIM1ATMCYP2D6KDM4E | |
| SCHEMBL11865850 | 0.84 | HTR2A (0.34) | HTR2APIM1ATMKDM4ECHRM2 | |
| SCHEMBL7874845 | 0.82 | — | — | |
| SCHEMBL13020958 | 0.82 | PIM1 (0.50) | PIM1ATMKDM4EHSD17B10MEN1 | |
| SCHEMBL11865231 | 0.80 | P2RX4 (0.39) | HTR2AATMCYP2D6HTR2CHTR2B | |
| SCHEMBL11873220 | 0.80 | ATM (0.34) | HTR2AATMCYP3A4NFKB1HSD17B10 | |
| SCHEMBL11871414 | 0.80 | CYP1A2 (0.37) | HTR2ACYP2D6KDM4ECYP3A4LMNA | |
| SCHEMBL11857695 | 0.80 | HTR2A (0.34) | HTR2APIM1ATMCYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | FMR LLC | 2017-01-05 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| EP-2966078-A2 | Inhibitors of histone deacetylase | MethylGene Inc. (CA) | 2016-01-13 | — | — | EP | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193749-B2 | Dibenzo[b,f][1,4]oxazepin-11-yl-N-hydroxybenzamides as HDAC inhibitors | FORUM PHARMACEUTICALS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-20020151553-A1 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-10-17 | — | — | US | disclosed |
| US-6433165-B1 | ANTIINFLAMMATORY AGENTS | MILLENNIUM PHARMACEUTICALS, INC. | 2002-08-13 | — | — | US | disclosed |
| US-6323206-B1 | ANTIINFLAMMATORY AGENTS AND VIRICIDES FOR AIDS WITH CYTOKINESAND CHEMOKINES | MILLENNIUM PHARMACEUTICALS, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-0497201-B1 | Tricyclic compounds and intermediates thereof | KYOWA HAKKO KOGYO KK (JP) | 1997-01-15 | — | — | EP | disclosed |
| US-5478835-A | Acyl coenzyme A: acyltransferase inhibitors; treatment of hyperlipemia and arteriosclerosis | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| US-5340807-A | Tricyclic compounds and intermediates thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-08-23 | — | — | US | disclosed |
| EP-0608198-A1 | Cyclic diphenylacetonenitriles as stabilisers | CIBA-GEIGY AG (CH) | 1994-07-27 | — | — | EP | disclosed |
| EP-0497201-A1 | Tricyclic compounds and intermediates thereof | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-3992445-A | ANTICONVULSANTS | MERCK & CO., INC. (US) | 1976-11-16 | — | — | US | disclosed |
| US-3988342-A | TRANQUILIZERS | MERCK & CO., INC. (US) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | HTR2A 231/4885PIM1 4557/4885ATM 1638/4885 |
| US-20170000749-A1 | Methods for Treating Cognitive Disorders Using Inhibitors of Histone Deacetylase | HDAC5, KAT2A, HDAC1 | HTR2A 259/4885PIM1 4593/4885ATM 1729/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | HTR2A 901/4885PIM1 4094/4885ATM 4462/4885 |
| US-20020151553-A1 | Chemokine receptor antagonists and methods of use therefor | CCR1, CCR2, CCR5 | HTR2A 2004/4885PIM1 2852/4885ATM 4444/4885 |
| US-20140011988-A1 | Dibenzo[B,F][1,4]Oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | HTR2A 901/4885PIM1 4094/4885ATM 4462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.